Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2020

View Archived Issues

Evaluation of 18F-FPIA, a radiotracer for SCFA metabolism, in fed and fasted healthy volunteers

Antiviral novaferon exhibits anti-SARS-CoV-2 effects both at cellular level and in COVID-19 patients

ValiRx presents full updated data from its phase I/II study of VAL-201 in prostate cancer

Braftovi and Mektovi approved in Japan for additional indication of BRAF-mutant colorectal cancer

Allena presents initial phase I data on ALLN-346 for hyperuricemia

Deciphera completes target enrollment in INTRIGUE trial of Qinlock in second-line GIST

Gain Therapeutics and UMSOM collaborate to develop novel STAR candidates

Voyager Therapeutics patents vector-based systems of augmenting protein destruction

Deepmind program can predict protein structures

Plus Therapeutics presents phase I data for RNL in recurrent glioblastoma

Kiniksa reports initial phase I data on KPL-404

Istari initiates phase II trial of PVSRIPO with pembrolizumab in recurrent GBM

Evinacumab shows promise in patients with refractory hypercholesterolemia

Galapagos reports topline phase II proof-of-concept data with GLPG-1205 in IPF

Lumicef approved in Japan for AS and nonradiographic axial spondyloarthritis

DMX-200 selected for inclusion in CLARITY 2.0 study for COVID-19

PTC initiates phase III study of vatiquinone for Friedreich's ataxia

Verastem opens phase II study of VS-6766 and defactinib in recurrent low-grade serous ovarian cancer

New phase IIb trial evaluates ability of AZD-8233 to lower LDL-C

New COMMUNITY adaptive platform trial for COVID-19 begins enrollment

Latexin expression promotes development of abdominal aortic aneurysm

Integral Early Discovery, Integral Health Holdings discover ZRANB1 inhibitors

New KCNT1 inhibitors identified at Praxis Precision Medicines

Nirsum Laboratories presents prodrugs of opioid receptor antagonists

New PDE6D inhibitors discovered at the University of Luxembourg

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...